From evidence-based medicine to clinical practice: not always straightforward

Bentzen, 2003, From clinical trials to clinical practice. A user's guide to evidence-based oncology, Eur J Cancer, 10.1016/S1359-6349(03)90012-7 Therasse, 2003, From clinical trials to clinical practice. From clinical trials to evidence-based medicine: how to build the evidence, Eur J Cancer, 10.1016/S1359-6349(03)90010-3 Buyse, 2003, From clinical trials to clinical practice: cornerstones of a well-designed phase III trial, Eur J Cancer, 10.1016/S1359-6349(03)90011-5 Browman, 1998, Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback, J Clin Oncol, 16, 1226, 10.1200/JCO.1998.16.3.1226 Bennett, 2003, Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations, J Clin Oncol, 21, 937, 10.1200/JCO.2003.07.165 Fervers, 2003, Clinical-practice guidelines in Europe: time for European cooperation for cancer guidelines, Lancet Oncol, 4, 139, 10.1016/S1470-2045(03)01017-9 Baar, 1989, Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials, J Clin Oncol, 7, 969, 10.1200/JCO.1989.7.7.969 Begg, 1996, Improving the quality of reporting of randomized controlled trials. The CONSORT statement, JAMA, 276, 637, 10.1001/jama.1996.03540080059030 1996, Checklist of information for inclusion in reports of clinical trials. The Asilomar Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature, Ann Intern Med, 124, 741, 10.7326/0003-4819-124-8-199604150-00007 Brundage, 1996, Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966–1993, J Clin Epidemiol, 49, 183, 10.1016/0895-4356(95)00518-8 Crawford, 1991, Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer, N Engl J Med, 325, 164, 10.1056/NEJM199107183250305 Tannock, 1996, False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons, J Natl Cancer Inst, 88, 206, 10.1093/jnci/88.3-4.206 Laurie, 1989, Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic, J Clin Oncol, 7, 1447, 10.1200/JCO.1989.7.10.1447 Moertel, 1990, Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Engl J Med, 322, 352, 10.1056/NEJM199002083220602 Tonkin, 1985, Criteria of tumor response used in clinical trials of chemotherapy, J Clin Oncol, 3, 870, 10.1200/JCO.1985.3.6.870 Moertel, 1976, The effect of measuring error on the results of therapeutic trials in advanced cancer, Cancer, 38, 388, 10.1002/1097-0142(197607)38:1<388::AID-CNCR2820380156>3.0.CO;2-A Warr, 1984, Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response, J Clin Oncol, 2, 1040, 10.1200/JCO.1984.2.9.1040 Krzyzanowska, 2003, Factors associated with failure to publish large randomized trials presented at an oncology meeting, JAMA, 290, 495, 10.1001/jama.290.4.495 Parmar, 1996, Assessing whether to perform a confirmatory randomized clinical trial, J Natl Cancer Inst, 88, 1645, 10.1093/jnci/88.22.1645 Baum, 2002, Decision-making in early breast cancer: guidelines and decision tools, Eur J Cancer, 38, 745, 10.1016/S0959-8049(02)00033-3 Naylor, 1992, Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?, Ann Intern Med, 117, 916, 10.7326/0003-4819-117-11-916 Rajagopal, 1994, Adjuvant chemotherapy for breast cancer: discordance between physicians' perception of benefit and the results of clinical trials, J Clin Oncol, 12, 1296, 10.1200/JCO.1994.12.6.1296 Slevin, 1990, Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public, BMJ, 300, 1458, 10.1136/bmj.300.6737.1458 Jansen, 2001, Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?, Br J Cancer, 84, 1577, 10.1054/bjoc.2001.1836 Hillner, 2000, Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care, J Clin Oncol, 18, 2327, 10.1200/JCO.2000.18.11.2327 Flanigan, 2001, Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer, N EngI J Med, 345, 1655, 10.1056/NEJMoa003013 Mickisch, 2001, Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon-alfa alone in metastatic renal-cell carcinoma: a randomised trial, Lancet, 358, 966, 10.1016/S0140-6736(01)06103-7 De Bellefeuille, 1992, The fate of abstracts submitted to a cancer meeting: factors which influence presentation and subsequent publication, Ann Oncol, 3, 187, 10.1093/oxfordjournals.annonc.a058147 Pitkin, 1999, Accuracy of data in abstracts of published research articles, JAMA, 281, 1110, 10.1001/jama.281.12.1110 Crump, 1996, Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes, J Clin Oncol, 14, 66, 10.1200/JCO.1996.14.1.66 Garcia-Carbonero, 1997, Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer, J Clin Oncol, 15, 3178, 10.1200/JCO.1997.15.10.3178 Rahman, 1997, Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standarddose doxorubicin-containing chemotherapy in patients with metastatic breast cancer, J Clin Oncol, 15, 3171, 10.1200/JCO.1997.15.10.3171 O'Brien, 2003, Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med, 348, 994, 10.1056/NEJMoa022457 Demetri, 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors, N EngI J Med, 347, 472, 10.1056/NEJMoa020461 Chlebowski, 1994, A decade of breast cancer clinical investigation: results as reported in the Program/Proceedings of the American Society of Clinical Oncology, J Clin Oncol, 12, 1789, 10.1200/JCO.1994.12.9.1789 Rosell, 1994, A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer, N Engl J Med, 330, 153, 10.1056/NEJM199401203300301 Roth, 1994, A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer, J Natl Cancer Inst, 86, 673, 10.1093/jnci/86.9.673 1995, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials, BMJ, 311, 899, 10.1136/bmj.311.7010.899 1999, Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: a randomised controlled trial, Lancet, 354, 533, 10.1016/S0140-6736(99)02292-8 Hall, 2002, Updated results of a randomised controlled trial of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer, 21, 178a Natale, 2001, Randomized phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer, 20, 2a 2003, Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis, Lancet, 361, 1922 von der Maase, 2000, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study, J Clin Oncol, 18, 3068, 10.1200/JCO.2000.18.17.3068 ATAC Investigators, 2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8 Citron, 2003, J Clin Oncol, 21, 1431, 10.1200/JCO.2003.09.081 Davis, 2000, Repopulation of tumour cells between cycles of chemotherapy: a neglected factor, Lancet Oncol, 1, 86, 10.1016/S1470-2045(00)00019-X Piccart, 2001, Taxanes in the adjuvant treatment of breast cancer: why not yet?, J Natl Cancer Inst Monogr, 30, 88, 10.1093/oxfordjournals.jncimonographs.a003468 Henderson, 2003, Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer, J Clin Oncol, 21, 976, 10.1200/JCO.2003.02.063